Mizoribine suppresses the progression of experimental peritoneal fibrosis in a rat model

Nephron - Experimental Nephrology

Volumn 112, Issue 2, 2009, Pages

  Takahashi, Shunsuke ^a   Taniguchi, Yoshihiko ^b   Nakashima, Ayumu ^a   Arakawa, Tetsuji ^a   Kawai, Toru ^a   Doi, Shigehiro ^a   Ito, Takafumi ^c   Masaki, Takao ^a   Kohno, Nobuoki ^a   Yorioka, Noriaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^c SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Experimental peritoneal fibrosis, rat model; Macrophage; Mizoribine; Peritoneal dialysis; Peritoneal fibrosis

Indexed keywords

ALCOHOL; ALPHA SMOOTH MUSCLE ACTIN; CHLORHEXIDINE GLUCONATE; COLLAGEN TYPE 3; MIZORIBINE; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; FEMALE; IMMUNOHISTOCHEMISTRY; MYOFIBROBLAST; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETROPERITONEAL FIBROSIS;

ACTINS; ANIMALS; CELL MOVEMENT; CHEMOKINE CCL2; CHLORHEXIDINE; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; IMMUNOSUPPRESSIVE AGENTS; MACROPHAGES, PERITONEAL; PERITONEAL DISEASES; PERITONEUM; RATS; RATS, WISTAR; RIBONUCLEOSIDES; TRANSFORMING GROWTH FACTOR BETA;

EID: 65449166463     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000213896     Document Type: Article

References (31)

1. Selgas R, Fernandez-Reyes MJ, Bosque E, Bajo MA, Borrego F, Jimenez C, Del Peso G, De Alvaro F: Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am JKidney Dis 1994;23: 64-73.
2. Davies SJ, Bryan J, Phillips L, Russell GI: Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dia l Transplant 1996;11: 498-506.
3. Ito T, Yorioka N: Peritoneal damage by peritoneal dialysis solutions. Clin Exp Nephrol 2008;12: 243-249.
4. Williams JD, Craig KJ, Topley N, Von Ruh-land C, Fallon M, Newman GR, Mackenzie RK, Williams GT: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13: 470-479.
5. Gandhi VC, Humayun HM, Ing TS, Daugir-das JT, Jablokow VR, Iwatsuki S, Geis WP, Hano JE: Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 1980;140: 1201-1203.
6. Kawanishi H, Moriishi M: Encapsulating peritoneal sclerosis: prevention and treatment. Perit Dial Int 2007;27(suppl 2): S289-S292.
7. Suga H, Teraoka S, Ota K, Komemushi S, Fu-ruta ni S, Yamauchi S, Ma rgolin S: Preventive effect of pirfenidone against experimental sclerosing peritonitis on rats. Exp Toxicol Pathol 1995;47: 287-291.
8. Mishima Y, Miyazaki M, Abe K, Ozono Y, Shioshita K, Xia Z, Harada T, Taguchi T, Koji T, Kohno S: Enhanced expression of heat shock protein 47 in rat model of peritoneal f ibrosis. Perit Dial Int 2003;23:14-22.
9. Koyama H, Tsuji M: Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells. Biochem Pharmacol 1983;32:3547-3553.
10. Kusumi T, Tsuda M, Katsunuma T, Yamamura M: Dual inhibitory effect of bredinin. Cell Biochem Funct 1989;7:201-204.
11. Ishikawa H: Mizoribine and mycophenolate mofetil. Curr Med Chem 1999;6:575-597.
12. Akiyama T, Okazaki H, Takahashi K, Hasegawa A, Tanabe K, Uchida K, Takahara S, Toma H: Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan. Transplant Proc 2005;37: 843-845.
13. Tanaka E, Inoue E, Kawaguchi Y, Tomatsu T, Yamanaka H, Hara M, Kamatani N: Acceptability and usefulness of mizoribine in the management of rheumatoid arthritis in methotrexate-refractory patients and elderly patients, based on analysis of data from a large-scale observational cohort study. Mod Rheumatol 2006;16:214-219.
14. Nakayamada S, Saito K, Umehara H, Ogawa N, Sumida T, Ito S, Minota S , Na ra H, Kondo H, Okada J, Mimori T, Yoshifuji H, Sano H, Hashimoto N, Sugai S, Tanaka Y: Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. Mod Rheumatol 2007;17: 464-469.
15. Tanaka H, Tsugawa K, Tsuruga K, Suzuki K, Nakahata T, Ito E, Waga S: Mizoribine for the treatment of lupus nephritis in children and adolescents. Clin Nephrol 2004;62: 412-417.
16. Honda M: Nephrotic syndrome and mizoribine in children. Pediatr Int 2002;44:210-216.
17. Sakai T, Kawamura T, Shirasawa T: Mizoribine improves renal tubulointerstitial fibrosis in unilateral ureteral obstruction-treated rat by inhibiting the infiltration of macrophages and the expression of α-smooth muscle actin. J Urol 1997;158: 2316-2322.
18. Sato N, Shiraiwa K, Kai K, Watanabe A, Ogawa S, Kobayashi Y, Yamagishi-Imai H, Utsunomiya Y, Mitarai T: Mizoribine ameliorates the tubulointerstitial fibrosis of obstructive nephropathy. Nephron 2001;89: 177-185.
19. Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, Harada T, Ozono Y, Koji T, Kohno S: Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int 2003; 64:887-896.
20. Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, Mizuta Y, Harada T, Ozono Y, Koji T, Kohno S: TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int 2004;66:1677-1685.
21. Doi S, Masaki T, Arakawa T, Takahashi S, Kawai T, Nakashima A, Naito T, Kohno N Yorioka N: Protective effects of peroxisome proliferator-activated receptor γ ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury. Transplantation 2007;84:207-213.
22. Hirai T, Masaki T, Kuratsune M, Yorioka N Kohno N: PDGF receptor tyrosine kinase inhibitor suppresses mesangial cell proliferation involving STAT3 activation. Clin Exp Immunol 2006;144:353-361.
23. Hosotsubo H, Takahara S, Taenaka N: Simplified high-performance liquid chromatographic method for determination of mizoribine in human serum. J Chromatography 1988;432: 340-345
24. Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Hyodo N, Suzuki S, Miura S: Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrol Dial Transplant 2005; 20:1573-1581.
25. Vaage J, Lindblad WJ: Production of collagen type I by mouse peritoneal macrophages. J Leukoc Biol 1990;48:274-280.
26. Nathan CF: Secretory products of macrophages. J Clin Invest 1987;79:319-326.
27. 1 in experimental hydronephrosis. Am J Physiol 1994;266:F926-F933.
28. 1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005;16: 425-436.
29. Yang AH, Chen JY, Lin JK: Myofibroblastic conversion of mesothelial cells. Kidney Int 2003;63: 1530-1539.
30. Stypinski D, Obaidi M, Combs M, Weber M, Stewart AJ, Ishikawa H: Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Br J Clin Pharmacol 2007;63:459-468.
31. Tanaka H, Tsugawa K, Nakahata T, Kudo M, Suzuki K, Ito E: Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis. Clin Nephrol 2005;63: 417-422.